Evidence map›Paper›PMID 41338180›Full record

ArticleHuman vaccines & immunotherapeutics2025

Immunogenicity of a recombinant subunit COVID-19 vaccine: A prospective, multi-centre, longitudinal study in Chinese Alzheimer's disease patients.

Youhong Weng, Yihua Huang, Jiangtao Zhang, Yahan Wu, Qing He, Sofia Litchev, Aimee Wu, Zongxin Ling, Longyou Zhao, Rongxian Liao and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Youhong WengDepartment of Clinic Laboratory, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
Yihua HuangDepartment of Clinic, Lishui Second People's Hospital Affiliated to Wenzhou Medical University, Lishui, China.
Jiangtao ZhangDepartment of Psychiatry, Zhejiang University School of Medicine and the Collaborative Innovation Center for Brain Science, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Yahan WuSchool of Basic Medicine and Forensics, Key Laboratory of Bio-Tech Vaccine of Zhejiang Province, Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College, Hangzhou, China.
Qing HeSchool of Basic Medicine and Forensics, Key Laboratory of Bio-Tech Vaccine of Zhejiang Province, Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College, Hangzhou, China.
Sofia LitchevDepartment of Chemistry & Biochemistry, University of California, Los Angeles, CA, USA.
Aimee WuDepartments of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Zongxin LingCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Longyou ZhaoDepartment of Clinic, Lishui Second People's Hospital Affiliated to Wenzhou Medical University, Lishui, China.
Rongxian LiaoMental Health Center, The Third Hospital of Quzhou, Quzhou, China.
Li ShaoSchool of Clinical Medicine, Institute of Hepatology and Metabolic Diseases, The Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Minchao WangDepartment of Clinic, Lishui Second People's Hospital Affiliated to Wenzhou Medical University, Lishui, China.
Yu XuMental Health Center, The Third Hospital of Quzhou, Quzhou, China.
Ruoyao GongMental Health Center, The Third Hospital of Quzhou, Quzhou, China.
Zhihua ZhangMental Health Center, The Third Hospital of Quzhou, Quzhou, China.
Yuwei WangMental Health Center, The Third Hospital of Quzhou, Quzhou, China.
Ting-Ting WuDepartments of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Shaohong LuSchool of Basic Medicine and Forensics, Key Laboratory of Bio-Tech Vaccine of Zhejiang Province, Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College, Hangzhou, China.
Qingming KongSchool of Basic Medicine and Forensics, Key Laboratory of Bio-Tech Vaccine of Zhejiang Province, Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College, Hangzhou, China.
Hao LvMental Health Center, The Third Hospital of Quzhou, Quzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination is an essential strategy against COVID-19 in the current era of emerging variants. This study evaluates the immunogenicity of the recombinant subunit COVID-19 vaccine (Zifivax) in Alzheimer's disease (AD) patients. A total of 249 patients with Alzheimer's disease (AD) were enrolled in an eight-month, prospective study conducted across three medical centers in Hangzhou, Zhejiang Province, from May 2022 to January 2023, Zhe Jiang province, and were categorized into unvaccinated (AD-UV) and vaccinated groups (AD-V). Levels of RBD-IgG, neutralization antibody activity, and cytokines were identified to evaluate the immune responses. Clinical outcomes were assessed within one month following breakthrough infection (BTI) with the Omicron variant. Following three doses, the vaccine induced a robust immune response, elevating neutralizing antibodies and activating T-cells in AD-V cohort. AD-V patients exhibited significantly higher humoral immune responses compared to AD-UV counterparts. The anti-RBD antibodies level and pseudoviral neutralizing activity demonstrated an increase concurrent with the onset of immunity and infection, and the seroresponse rate exhibited a similar trend in AD-V cohort. RBD-IgG antibody levels against WT, DELTA, and BA.5 variants in AD-V cohort showed significantly higher compared to AD-UV cohort. Following Omicron infection, unvaccinated patients experienced higher levels of Th1/Th2-type cytokines than vaccinated individuals. Vaccination correlated with reduced severe illness, increased survival rates and extended survival times after Omicron BTI. The findings highlight the immunogenicity and suggest a certain degree of protective effectiveness of the recombinant subunit COVID-19 vaccine (Zifivax) in AD patients.

Indexed as

Alzheimer DiseaseCOVID-19COVID-19 VaccinesImmunogenicity, VaccineAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralChinaCytokinesEast Asian PeopleFemaleHumansImmunoglobulin GLongitudinal StudiesMaleAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCytokinesImmunoglobulin GVaccines, SubunitVaccines, SyntheticAlzheimer’s diseasecellular immunityCOVID-19humoral immunityOmicron infectionSARS-CoV-2vaccine

Identifiers

PMID41338180
PMCPMC12688218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.